Changes in antidepressant metabolism and dosing across pregnancy and early postpartum - PubMed (original) (raw)
Clinical Trial
Changes in antidepressant metabolism and dosing across pregnancy and early postpartum
Dorothy K Sit et al. J Clin Psychiatry. 2008 Apr.
Abstract
Objective: Little information about the disposition of individual antidepressant drugs during pregnancy has been published. We examined the dose requirements and level-to-dose (L/D) ratios of citalopram, escitalopram, and sertraline during pregnancy and after birth.
Method: Women aged from 32 to 43 years with major depressive disorder according to the Structured Clinical Interview for DSM-IV Axis I Disorders participated in the study. Doses were charted across each week of gestation and post-partum. Samples were collected at 20, 30, and 36 weeks' gestation; delivery; and at 2 and 12 weeks postpartum. Plasma trough levels were obtained 8 to 15 hours after dose intake. Across pregnancy and postpartum, the mean dose-corrected plasma concentrations (L/D ratios) of S- and R-citalopram and S-sertraline, and the corresponding primary chiral metabolites S- and R-desmethylcitalopram and N-desmethylsertra-line were assessed. The samples were analyzed for concentrations of stereospecific parent drug and metabolites. The study was conducted from 2003 to 2006.
Results: Three women received citalopram, 2 women were treated with escitalopram, and 6 women received sertraline. In 4 of 5 subjects who received citalopram or escitalopram and 5 of 6 subjects who received sertraline, the L/D ratios for the stereoisomers of the parent compound and primary metabolite decreased between 20 weeks gestation and delivery, which reflects increased drug metabolism. By 12 weeks postpartum the L/D ratios were similar to those detected at 20 weeks gestation.
Conclusions: Our cases illustrate that dose requirements frequently increase during the second half of pregnancy to offset increased drug turnover and maintain optimal pharmacotherapy. These findings replicate and extend earlier published data with other antidepressants.
Trial registration: clinicaltrials.gov Identifier: NCT00279370.
Figures
Figure 1
Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Citalopram-Treated Women
Figure 2
Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Escitalopram-Treated Women
Figure 3
Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Sertraline-Treated Women
Comment in
- Perinatal psychiatry: risk factors, treatment data, and specific challenges for clinical researchers.
Freeman MP. Freeman MP. J Clin Psychiatry. 2008 Apr;69(4):633-4. J Clin Psychiatry. 2008. PMID: 18507486 No abstract available.
Similar articles
- A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Sanchez C, Reines EH, Montgomery SA. Sanchez C, et al. Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Int Clin Psychopharmacol. 2014. PMID: 24424469 Free PMC article. Review. - [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM, Llorca PM, Despiegel N, Verpillat P. Azorin JM, et al. Encephale. 2004 Mar-Apr;30(2):158-66. doi: 10.1016/s0013-7006(04)95427-9. Encephale. 2004. PMID: 15107719 Clinical Trial. French. - International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E. Williams LM, et al. Trials. 2011 Jan 5;12:4. doi: 10.1186/1745-6215-12-4. Trials. 2011. PMID: 21208417 Free PMC article. Clinical Trial. - Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J, Goa KL. Waugh J, et al. CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004. CNS Drugs. 2003. PMID: 12665392 Review. - Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
Sit D, Perel JM, Luther JF, Wisniewski SR, Helsel JC, Wisner KL. Sit D, et al. J Clin Psychopharmacol. 2010 Aug;30(4):381-6. doi: 10.1097/JCP.0b013e3181e7be23. J Clin Psychopharmacol. 2010. PMID: 20631556 Free PMC article. Clinical Trial.
Cited by
- Relevance of pharmacogenetic analyses and therapeutic drug monitoring of antidepressants for an individualized treatment of peripartum psychopathology.
Colombo A, Cafaro R, Di Bernardo I, Mereghetti M, Cerolini L, Giacovelli L, Giorgetti F, Vanzetto S, Girone N, Savasi V, Cetin I, Clementi E, Bosi MF, Viganò CA, Dell'Osso B. Colombo A, et al. Int Clin Psychopharmacol. 2024 Mar 1;39(2):106-112. doi: 10.1097/YIC.0000000000000520. Epub 2023 Nov 20. Int Clin Psychopharmacol. 2024. PMID: 37982307 Free PMC article. - Switching pattern and dose adjustment of antidepressants before and during pregnancy.
Robiyanto R, Roos M, Bos JHJ, Hak E, van Puijenbroek EP, Schuiling-Veninga CCM. Robiyanto R, et al. Arch Womens Ment Health. 2023 Oct;26(5):685-696. doi: 10.1007/s00737-023-01355-8. Epub 2023 Aug 5. Arch Womens Ment Health. 2023. PMID: 37542677 Free PMC article. - Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments.
Frohman DFT, Nnah K, Tsirka SE. Frohman DFT, et al. Handb Exp Pharmacol. 2023;282:163-180. doi: 10.1007/164_2023_670. Handb Exp Pharmacol. 2023. PMID: 37439845 - Pharmacokinetics of Antidepressants in Pregnancy.
Yue M, Kus L, Katta S, Su I, Li L, Haas DM, Quinney SK. Yue M, et al. J Clin Pharmacol. 2023 Jun;63 Suppl 1(Suppl 1):S137-S158. doi: 10.1002/jcph.2282. J Clin Pharmacol. 2023. PMID: 37317494 Free PMC article. Review. - Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort.
Brumbaugh JE, Ball CT, Crook JE, Stoppel CJ, Carey WA, Bobo WV. Brumbaugh JE, et al. Mayo Clin Proc Innov Qual Outcomes. 2023 Mar 7;7(2):127-139. doi: 10.1016/j.mayocpiqo.2023.02.002. eCollection 2023 Apr. Mayo Clin Proc Innov Qual Outcomes. 2023. PMID: 36938114 Free PMC article.
References
- U.S. Food and Drug Administration. Pharmacokinetics in Pregnancy: Study Design, Data Analysis, and Impact on Dosing and Labeling. US Dept Health Human Services; 2004. October Issue, Guidance for Industry; pp. 1–14.
- Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150:1541–1542. - PubMed
- Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997;33:243–248. - PubMed
- Hostetter A, Stowe ZN, Strader JR, Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11:51–57. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 5 R25 MH060473-08/MH/NIMH NIH HHS/United States
- R25 MH060473/MH/NIMH NIH HHS/United States
- R01 MH060335-03/MH/NIMH NIH HHS/United States
- R01 MH060335-04/MH/NIMH NIH HHS/United States
- R01 MH060335-02/MH/NIMH NIH HHS/United States
- R01 MH60335/MH/NIMH NIH HHS/United States
- R01 MH060335-01/MH/NIMH NIH HHS/United States
- R01 MH060335/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials